Ophthotech Names Michael Atieh CFO, Succeeding Bruce Peacock - Quick Facts

(RTTNews) - Ophthotech Corp. (OPHT), a biopharmaceutical company specializing for treating eye diseases, announced Tuesday that it has appointed Michael Atieh as Executive Vice President, Chief Financial and Business Officer and Treasurer, effective September 30.

Atieh replaces Bruce Peacock, Chief Financial and Business Officer and Treasurer, who has notified the company of his intention to retire effective September 30.

Atieh spent the majority of his career in the pharmaceutical industry with Merck and Co., Inc. (MRK), where he held various senior level positions over a 20 year period.

Atieh served as Executive Chairman of Eyetech Inc. from 2009 until the Company was acquired by Valeant Pharmaceuticals in 2012, Executive Vice President and Chief Financial Officer of OSI Pharmaceuticals from 2005 until 2009 and was Senior Vice President and Chief Financial Officer, and Group President at Dendrite International from 2000 until 2004.

Peacock stated, "It has been a pleasure working with David Guyer, Samir Patel and the entire Ophthotech team as the Company grew from being a private, start-up organization to completing one of the largest biotech initial public offerings by deal size and market capitalization in 2013, establishing a strong financial foundation, and executing one of the largest ex-US partnering deals in the biotechnology industry as we entered into a licensing and commercialization agreement with Novartis for the treatment of wet AMD."